Trials / Completed
CompletedNCT05869669
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 159 (actual)
- Sponsor
- EIP Pharma Inc · Industry
- Sex
- All
- Age
- 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neflamapimod | Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules |
| DRUG | Placebo | Placebo is a capsule that looks just like neflamapimod but without the active ingredients |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2025-05-29
- Completion
- 2025-06-16
- First posted
- 2023-05-22
- Last updated
- 2026-04-06
Locations
40 sites across 3 countries: United States, Netherlands, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05869669. Inclusion in this directory is not an endorsement.